%0 Journal Article
%T The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
%A Arnaud M
%A Bobisse S
%A Chiffelle J
%A Harari A
%J Front Immunol
%V 12
%N 0
%D 2021
%M 34394096
%F 8.786
%R 10.3389/fimmu.2021.701636
%X Mutation-derived neoantigens are now established as attractive targets for cancer immunotherapy. The field of adoptive T cell transfer (ACT) therapy was significantly reshaped by tumor neoantigens and is now moving towards the genetic engineering of T cells with neoantigen-specific T cell receptors (TCRs). Yet, the identification of neoantigen-reactive TCRs remains challenging and the process needs to be adapted to clinical timelines. In addition, the state of recipient T cells for TCR transduction is critical and can affect TCR-ACT efficacy. Here we provide an overview of the main strategies for TCR-engineering, describe the selection and expansion of optimal carrier cells for TCR-ACT and discuss the next-generation methods for rapid identification of relevant TCR candidates for gene transfer therapy.